5Vote!
PR News Wire (Free subscription) | 11/02/2009
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira...
5Vote!
Drug and Device Law (Free subscription) | 12/07/2009
We just stumbled across Mohr v. Targeted Genetics, No. 09-3170, 2009 LEXIS 107761 (C.D. Ill. Nov. 18, 2009), and thought we'd share that small Iqbal win. Jolee Mohr was enrolled in a clinical trial for an investigational gene therapy for rheumatoid arthritis. While Mohr was in the trial, her treating physician prescribed Abbott's rheumatoid arthritis drug, Humira, for her. Mohr died on July...
5Vote!
Market Wire (Free subscription) | 12/08/2009
REDWOOD CITY, CA (MARKET WIRE) Facet Biotech Corporation (NASDAQ: FACT) announced today its presentation of data regarding the company's proprietary next-generation protein engineering capabilities, including its PxP engineering technology, and identification of multiple novel optimized variants of four commercial antibodies: bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), adalimumab (Humira(R))...
5Vote!
Brass and Ivory (Free subscription) | 12/01/2009
... arthritis who have had an inadequate response to one or more TNF antagonist therapies (such as Humira, Enbrel, or Remicade). Those of us living with multiple sclerosis CANNOT use one of the anti-TNF disease-modifying anti-rheumatic drugs (DMARDs) which are commonly used in the treatment of RA or other rheumatic diseases. This is because the anti-TNF drugs are known to increase disease activity...
7Vote!
Patently-O: Patent Law Blog (Free subscription) | 11/16/2009
... billion judgment against Abbott based on the jury's findings that Abbott's arthritis treatment Humira infringes Centocor's U.S. Patent No. 7,070,775. In a post-trial verdict, Judge Ward has rejected Abbott's defenses of inequitable conduct and laches. An appeal to the Federal Circuit will follow. [ MCSmith ][ Patently-O Discussion of the Verdict ] . Medela v. Kinetic Concepts : The Supreme...
4Vote!
PR News Wire (Free subscription) | 11/11/2009
... alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira. Humira will suffer the most as the agent garners use as a second-line biologic therapy following Enbrel and surveyed dermatologists indicate that more of their Stelara prescriptions will be as a second-line biologic agent than as a first-line biologic.
5Vote!
Fool.com (Free subscription) | 11/10/2009
ALD518 targets interleukin-6 (IL-6), a molecule that promotes inflammation in rheumatoid arthritis patients. The companies say that the drug has a "novel mechanism of action," but that's only because Roche's IL-6 targeting drug, Actemra, is still under review by the Food and Drug Administration. It's possible that all drugs that target the same molecule could become blockbusters: Abbott Labs' Humira,...
3Vote!
Xconomy (Free subscription) | 11/10/2009
... protein called TNF, like Amgen’s etanercept (Enbrel) and Abbott Laboratories’ adalimumab (Humira). Analysts have predicted sales of the Roche drug could capture a tidy portion of this huge market, with sales of $2 billion a year. Alder has designed its antibody to block the IL-6 protein target. The Alder drug, ALD518, is designed to last longer in the bloodstream, so it can be given less...
7Vote!
Pharmalot (Free subscription) | 11/10/2009
... on Lyrica; and $146.9 million on Ambien. The ‘most referenced’ DTC brands were Boniva, Enbrel, Humira and Reclast, with Detrol LA and Gardasil tied for fifth place. Patients, meanwhile, most often brought up side effect concerns arising from fair balance statements in Advair TV spots. Such as? “I saw on TV that Advair can cause pneumonia in some patients.” And Ambien, another of the most...
3Vote!
Xconomy (Free subscription) | 11/11/2009
... class of biotech drugs, like Amgen’s etanercept (Enbrel) and Abbott Laboratories’ adalimumab (Humira). When asked directly whether Alder’s clinical trial shows it is competitive with the Amgen and Abbott drugs, Schatzman said this: “We think we’re going to give them a run for their money.” Seattle Genetics co-founder and CEO Clay Siegall , an Alder board member, added, “This is a superb...
4Vote!
PR News Wire (Free subscription) | 11/02/2009
... in separate trials for TNF-alpha inhibitors such as Amgen/Pfizer's Enbrel and Abbott's Humira, the two leading agents in the rheumatoid arthritis drug market.
5Vote!
They gave us a republic (Free subscription) | 10/28/2009
... required hospitalization for a flare that she attributed to not being able to afford the month's Humira, a biologic medicine used to treat severe, active Crohn's disease. The drug is priced by Abbott Laboratories at a staggering $22,000 a year. This patient would clearly have benefited from the availability of an affordable, generic version. SNIP Current biologics proposals, as they stand,...
